Reply to Woodward Et Al.: A Standard Mastectomy Should Not Be the Only Recommended Breast Surgical Treatment for Non-Metastatic Inflammatory Breast Cancer

Hongliang Chen,Kejin Wu,Maoli Wang,Fuwen Wang,Mingdi Zhang,Peng Zhang

DOI: https://doi.org/10.1016/j.breast.2018.02.031

2018-01-01

Abstract:Dr Woodward et al. [ [1] Woodward W.A. Ueno N.T. Kuerer H.M. Lucci A. Shen Y. Reply to ‘A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: a large population-based study in the Surveillance, Epidemiology, and End Results database 18’. Breast. 2018; 39: 148-149 Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar ] insisted that breast conserving surgery (BCS) should not be offered to inflammatory breast cancer (IBC). Although BCS remains controversial in IBC, there were studies that reported successful BCS and immediate reconstruction (IR) in well-selected IBC [ 2 Bonev V. Evangelista M. Chen J.H. Su M.Y. Lane K. Mehta R. et al. Long-term follow-up of breast-conserving therapy in patients with inflammatory breast cancer treated with neoadjuvant chemotherapy. Am Surg. 2014; 80: 940-943 PubMed Google Scholar , 3 Brzezinska M. Williams L.J. Thomas J. Michael Dixon J. Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery. Breast Canc Res Treat. 2016; 160: 387-391 Crossref PubMed Scopus (24) Google Scholar , 4 Chin P.L. Andersen J.S. Somlo G. Chu D.Z. Schwarz R.E. Ellenhorn J.D. Esthetic reconstruction after mastectomy for inflammatory breast cancer: is it worthwhile?. J Am Coll Surg. 2000; 190: 304-309 Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar , 5 Simpson A.B. McCray D. Wengler C. Crowe J.P. Djohan R. Tendulkar R. et al. Immediate reconstruction in inflammatory breast cancer: challenging current care. Ann Surg Oncol. 2016; 23: 642-648 Crossref PubMed Scopus (11) Google Scholar ]. IBC is a clinical diagnosis representing a broad spectrum of disease presentation. It tends to progress quickly and could not get a negative surgical margin if it does not respond well to the initial neoadjuvant treatment. In such condition, it usually predicts a poor survival. With the great improvement in the neoadjuvant chemotherapy (NAC), radiotherapy (RT) post or prior to surgery and imaging technology such as MRI and PET [ [6] van Uden D.J.P. de Wilt J.H.W. Meeuwis C. Blanken-Peeters C. Mann R.M. Dynamic contrast-enhanced magnetic resonance imaging in the assessment of inflammatory breast cancer prior to and after neoadjuvant treatment. Breast Care. 2017; 12: 224-229 Crossref PubMed Scopus (9) Google Scholar , [7] Champion L. Lerebours F. Alberini J.L. Fourme E. Gontier E. Bertrand F. et al. 18F-FDG PET/CT to predict response to neoadjuvant chemotherapy and prognosis in inflammatory breast cancer. J Nucl Med Off Publ Soc Nucl Med. 2015; 56: 1315-1321 PubMed Google Scholar ], more patients will respond well and residual tumors could be detected more precisely. For patients who respond well to the initial therapy which probably predicts a better survival, there is no reason to reject BCS [ [8] Rea D. Francis A. Hanby A.M. Speirs V. Rakha E. Shaaban A. et al. Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Br J Canc. 2015; 112: 1613-1615 Crossref PubMed Scopus (29) Google Scholar ] or IR completely. In USA, Bonev et al. suggested that the overall survival rate for BCS and mastectomy for IBC patients was 59% and 57% (P = 0.49) at a median follow-up of 60 months and BCS could be considered in a selected group of patients who demonstrate a good response to NAC [ [2] Bonev V. Evangelista M. Chen J.H. Su M.Y. Lane K. Mehta R. et al. Long-term follow-up of breast-conserving therapy in patients with inflammatory breast cancer treated with neoadjuvant chemotherapy. Am Surg. 2014; 80: 940-943 PubMed Google Scholar ]. And in Europe, Brzezinska et al. indicated that IBC was not an absolute contraindication to BCS and locoregional recurrence in patients after BCS appeared part of widespread recurrent disease rather than inadequate local treatment [ [3] Brzezinska M. Williams L.J. Thomas J. Michael Dixon J. Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery. Breast Canc Res Treat. 2016; 160: 387-391 Crossref PubMed Scopus (24) Google Scholar ]. In previous studies based on SEER database, it was suggested that segmental surgery had a poorer survival compared with mastectomy in IBC. However, these studies included many IBC patients who did not receive any form of radiation, and these studies had no information of chemotherapy [ [9] Dawood S. Ueno N.T. Valero V. Woodward W.A. Buchholz T.A. Hortobagyi G.N. et al. Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2012; 23: 870-875 Crossref PubMed Scopus (41) Google Scholar , [10] Dawood S. Lei X. Dent R. Gupta S. Sirohi B. Cortes J. et al. Survival of women with inflammatory breast cancer: a large population-based study. Ann Oncol Off J Eur Soc Med Oncol. 2014; 25: 1143-1151 Crossref PubMed Scopus (50) Google Scholar ].